Sanofi and Regeneron likely to cough up royalties to end Amgen’s PCSK9 patent suit: Analyst

Tracy Staton One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from Sanofi and Regeneron. They're apparently ...

Teva scores European patent victory for long-acting Copaxone

Carly Helfand After fighting a long battle over the IP shield on lead drug Copaxone, Teva is feeling the heat from generics makers over the patent on its new, long-acting ...

UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

Tracy Staton The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster ...

Celgene fights for sanction on patent challenger Bass

Carly Helfand Celgene is hedge fund manager Kyle Bass' latest patent target, it says–but the biotech isn't taking the news lying down. FiercePharma News

J&J’s 2018 Remicade patent smacked down at PTO again

Tracy Staton Johnson & Johnson said the U.S. Patent and Trademark Office rejected a 2018 Remicade patent for the second time, putting the blockbuster anti-inflammatory's exclusivity ...

As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

John Carroll The cascade of venture cash into CRISPR-Cas9 startups is continuing with no end in sight, despite a patent brawl brewing over who owns the technology. Today it's CRISPR ...

Shire’s Lialda, Gattex are hedge funder’s latest patent targets

Tracy Staton Hedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics drug, Bass asked the U.S. Patent ...

Daiichi’s new clot-fighter Savaysa can’t make up for $2.6B Benicar patent loss: analysts

Carly Helfand Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment Benicar set to lose patent protection next year. A black-box warning on its new drug Savaysa ...

India’s Cipla presses court to not honor Novartis Onbrez patent citing Lupin license deal

EJ Lane India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss ...

Pfizer turns back Mylan’s patent challenge to Sutent

Eric Palmer Pfizer execs can sigh with relief now that a federal court has backed the company's patents on kidney cancer drug Sutent. The med has become increasingly important to ...

Bristol-Myers catches a break as Indian agency delays Sprycel patent decision

Eric Palmer Prime Minister Narendra Modi got an ear full from both constituents and the U.S. drug industry about India's approach to drug patents during his first visit to the U.S. ...

Idenix takes to Europe with its Gilead patent spat

Damian Garde Idenix Pharmaceuticals believes Gilead Sciences violated its patents with the blockbuster-selling hepatitis C pill Sovaldi, and the biotech has expanded its legal fight ...
Page 1 of 612345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS